{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T13:53:16Z","timestamp":1767707596707,"version":"3.48.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T00:00:00Z","timestamp":1764201600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T00:00:00Z","timestamp":1767657600000},"content-version":"vor","delay-in-days":40,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-025-14885-4","type":"journal-article","created":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T11:25:49Z","timestamp":1764242749000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Prevalence and therapeutic response of EGFR T790I mutation in NSCLC patients with acquired resistance to EGFR-TKIs: a retrospective cohort study"],"prefix":"10.1186","volume":"26","author":[{"given":"Jingwei","family":"Shi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ye","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiaohui","family":"Pang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiani C.","family":"Yin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chunhong","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haiyan","family":"Xie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,27]]},"reference":[{"issue":"9","key":"14885_CR1","first-page":"2892","volume":"5","author":"A Midha","year":"2015","unstructured":"Midha A, Dearden S, McCormack R. EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: a systematic review and global map by ethnicity (mutMapII). Am J Cancer Res. 2015;5(9):2892\u2013911.","journal-title":"Am J Cancer Res"},{"issue":"4","key":"14885_CR2","doi-asserted-by":"publisher","first-page":"249","DOI":"10.6004\/jnccn.2204.0023","volume":"22","author":"GJ Riely","year":"2024","unstructured":"Riely GJ, Wood DE, Ettinger DS, Aisner DL, Akerley W, Bauman JR, et al. Non-Small cell lung cancer, version 4.2024, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2024;22(4):249\u201374.","journal-title":"J Natl Compr Canc Netw"},{"doi-asserted-by":"crossref","unstructured":"Chen S, Wang Z, Sun B. Chinese society of clinical oncology Non-small cell lung cancer (CSCO NSCLC) guidelines in 2024: key update on the management of early and locally advanced NSCLC. Cancer Biol Med. 2025;22(3):191-6.","key":"14885_CR3","DOI":"10.20892\/j.issn.2095-3941.2024.0592"},{"issue":"1","key":"14885_CR4","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1056\/NEJMoa1913662","volume":"382","author":"SS Ramalingam","year":"2020","unstructured":"Ramalingam SS, Vansteenkiste J, Planchard D, Cho BC, Gray JE, Ohe Y, et al. Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC. N Engl J Med. 2020;382(1):41\u201350.","journal-title":"N Engl J Med"},{"issue":"4","key":"14885_CR5","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1016\/j.jtho.2015.12.103","volume":"11","author":"JJ Lin","year":"2016","unstructured":"Lin JJ, Cardarella S, Lydon CA, Dahlberg SE, Jackman DM, J\u00e4nne PA, et al. Five-year survival in EGFR-mutant metastatic lung adenocarcinoma treated with EGFR-TKIs. J Thorac Oncol. 2016;11(4):556\u201365.","journal-title":"J Thorac Oncol"},{"key":"14885_CR6","doi-asserted-by":"publisher","first-page":"40374","DOI":"10.1038\/srep40374","volume":"7","author":"D Zhao","year":"2017","unstructured":"Zhao D, Chen X, Qin N, Su D, Zhou L, Zhang Q, et al. The prognostic role of EGFR-TKIs for patients with advanced non-small cell lung cancer. Sci Rep. 2017;7:40374.","journal-title":"Sci Rep"},{"issue":"75","key":"14885_CR7","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3002003","volume":"3","author":"LV Sequist","year":"2011","unstructured":"Sequist LV, Waltman BA, Dias-Santagata D, Digumarthy S, Turke AB, Fidias P, et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med. 2011;3(75): 75ra26.","journal-title":"Sci Transl Med"},{"issue":"8","key":"14885_CR8","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1200\/JCO.2012.43.3912","volume":"31","author":"K Ohashi","year":"2013","unstructured":"Ohashi K, Maruvka YE, Michor F, Pao W. Epidermal growth factor receptor tyrosine kinase inhibitor-resistant disease. J Clin Oncol. 2013;31(8):1070\u201380.","journal-title":"J Clin Oncol"},{"issue":"8","key":"14885_CR9","doi-asserted-by":"publisher","first-page":"2240","DOI":"10.1158\/1078-0432.CCR-12-2246","volume":"19","author":"HA Yu","year":"2013","unstructured":"Yu HA, Arcila ME, Rekhtman N, Sima CS, Zakowski MF, Pao W, et al. Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clin Cancer Res. 2013;19(8):2240\u20137.","journal-title":"Clin Cancer Res"},{"issue":"7","key":"14885_CR10","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1056\/NEJMoa1612674","volume":"376","author":"TS Mok","year":"2017","unstructured":"Mok TS, Wu YL, Ahn MJ, Garassino MC, Kim HR, Ramalingam SS, et al. Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer. N Engl J Med. 2017;376(7):629\u201340.","journal-title":"N Engl J Med"},{"issue":"7","key":"14885_CR11","volume":"2","author":"C Xiang","year":"2021","unstructured":"Xiang C, Zhang W, Xiong LW, Cai XW, Teng HH, Zhao RY, et al. EGFR Thr790Leu as a potential resistance mechanism to first-generation EGFR tyrosine kinase inhibitor may respond to osimertinib in patients with lung adenocarcinoma. JTO Clin Res Rep. 2021;2(7): 100185.","journal-title":"JTO Clin Res Rep"},{"key":"14885_CR12","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.727312","volume":"11","author":"Y Wang","year":"2021","unstructured":"Wang Y, Liu S, Feng A, Luo H, Hu J, Wang K, et al. Identification of a rare EGFR T790I mutation in lung adenocarcinoma sensitive to osimertinib. Front Oncol. 2021;11: 727312.","journal-title":"Front Oncol"},{"issue":"5","key":"14885_CR13","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","volume":"2","author":"E Cerami","year":"2012","unstructured":"Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012;2(5):401\u20134.","journal-title":"Cancer Discov"},{"issue":"Database issue","key":"14885_CR14","doi-asserted-by":"publisher","first-page":"D805","DOI":"10.1093\/nar\/gku1075","volume":"43","author":"SA Forbes","year":"2015","unstructured":"Forbes SA, Beare D, Gunasekaran P, Leung K, Bindal N, Boutselakis H, et al. COSMIC: exploring the world\u2019s knowledge of somatic mutations in human cancer. Nucleic Acids Res. 2015;43(Database issue):D805\u201311.","journal-title":"Nucleic Acids Res"},{"issue":"15","key":"14885_CR15","doi-asserted-by":"publisher","first-page":"2114","DOI":"10.1093\/bioinformatics\/btu170","volume":"30","author":"AM Bolger","year":"2014","unstructured":"Bolger AM, Lohse M, Usadel B. Trimmomatic: a flexible trimmer for illumina sequence data. Bioinformatics. 2014;30(15):2114\u201320.","journal-title":"Bioinformatics"},{"issue":"9","key":"14885_CR16","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1101\/gr.107524.110","volume":"20","author":"A McKenna","year":"2010","unstructured":"McKenna A, Hanna M, Banks E, Sivachenko A, Cibulskis K, Kernytsky A, et al. The genome analysis toolkit: a mapreduce framework for analyzing next-generation DNA sequencing data. Genome Res. 2010;20(9):1297\u2013303.","journal-title":"Genome Res"},{"issue":"3","key":"14885_CR17","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1101\/gr.129684.111","volume":"22","author":"DC Koboldt","year":"2012","unstructured":"Koboldt DC, Zhang Q, Larson DE, Shen D, McLellan MD, Lin L, et al. Varscan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing. Genome Res. 2012;22(3):568\u201376.","journal-title":"Genome Res"},{"issue":"1","key":"14885_CR18","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/s13045-021-01089-z","volume":"14","author":"G Chen","year":"2021","unstructured":"Chen G, Peng J, Xiao Q, Wu HX, Wu X, Wang F, et al. Postoperative circulating tumor DNA as markers of recurrence risk in stages II to III colorectal cancer. J Hematol Oncol. 2021;14(1):80.","journal-title":"J Hematol Oncol"},{"issue":"18","key":"14885_CR19","doi-asserted-by":"publisher","first-page":"i333","DOI":"10.1093\/bioinformatics\/bts378","volume":"28","author":"T Rausch","year":"2012","unstructured":"Rausch T, Zichner T, Schlattl A, St\u00fctz AM, Benes V, Korbel JO. Delly: structural variant discovery by integrated paired-end and split-read analysis. Bioinformatics. 2012;28(18):i333-9.","journal-title":"Bioinformatics"},{"issue":"2","key":"14885_CR20","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1093\/bib\/bbs017","volume":"14","author":"H Thorvaldsd\u00f3ttir","year":"2013","unstructured":"Thorvaldsd\u00f3ttir H, Robinson JT, Mesirov JP. Integrative genomics viewer (IGV): high-performance genomics data visualization and exploration. Brief Bioinform. 2013;14(2):178\u201392.","journal-title":"Brief Bioinform"},{"issue":"4","key":"14885_CR21","doi-asserted-by":"publisher","first-page":"e1004873","DOI":"10.1371\/journal.pcbi.1004873","volume":"12","author":"E Talevich","year":"2016","unstructured":"Talevich E, Shain AH, Botton T, Bastian BC, CNVkit. Genome-Wide copy number detection and visualization from targeted DNA sequencing. PLoS Comput Biol. 2016;12(4):e1004873.","journal-title":"PLoS Comput Biol"},{"issue":"11","key":"14885_CR22","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.1016\/S1470-2045(17)30608-3","volume":"18","author":"YL Wu","year":"2017","unstructured":"Wu YL, Cheng Y, Zhou X, Lee KH, Nakagawa K, Niho S, et al. Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial. Lancet Oncol. 2017;18(11):1454\u201366.","journal-title":"Lancet Oncol"},{"issue":"5","key":"14885_CR23","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/S1470-2045(16)30033-X","volume":"17","author":"K Park","year":"2016","unstructured":"Park K, Tan EH, O\u2019Byrne K, Zhang L, Boyer M, Mok T, et al. Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial. Lancet Oncol. 2016;17(5):577\u201389.","journal-title":"Lancet Oncol"},{"issue":"27","key":"14885_CR24","doi-asserted-by":"publisher","first-page":"3162","DOI":"10.1200\/JCO.21.02641","volume":"40","author":"S Lu","year":"2022","unstructured":"Lu S, Dong X, Jian H, Chen J, Chen G, Sun Y, et al. AENEAS: a randomized phase III trial of aumolertinib versus gefitinib as first-line therapy for locally advanced or metastaticnon-small-cell lung cancer with EGFR exon 19 deletion or L858R mutations. J Clin Oncol. 2022;40(27):3162\u201371.","journal-title":"J Clin Oncol"},{"issue":"9","key":"14885_CR25","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1016\/j.ccell.2021.07.005","volume":"39","author":"Q Zhou","year":"2021","unstructured":"Zhou Q, Xu CR, Cheng Y, Liu YP, Chen GY, Cui JW, et al. Bevacizumab plus erlotinib in Chinese patients with untreated, EGFR-mutated, advanced NSCLC (ARTEMIS-CTONG1509): A multicenter phase 3 study. Cancer Cell. 2021;39(9):1279\u2013e913.","journal-title":"Cancer Cell"},{"unstructured":"Eser PO, editor. Characterizing resistance and sensitivity to targeted therapies in patient-derived models of EGFR mutant lung cancer2018.","key":"14885_CR26"},{"issue":"6","key":"14885_CR27","doi-asserted-by":"publisher","first-page":"2850","DOI":"10.1021\/acs.jcim.9b00361","volume":"59","author":"S Kannan","year":"2019","unstructured":"Kannan S, Fox SJ, Verma CS. Exploring gatekeeper mutations in EGFR through computer simulations. J Chem Inf Model. 2019;59(6):2850\u20138.","journal-title":"J Chem Inf Model"},{"issue":"90","key":"14885_CR28","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3002356","volume":"3","author":"J Chmielecki","year":"2011","unstructured":"Chmielecki J, Foo J, Oxnard GR, Hutchinson K, Ohashi K, Somwar R, et al. Optimization of dosing for EGFR-mutant non-small cell lung cancer with evolutionary cancer modeling. Sci Transl Med. 2011;3(90): 90ra59.","journal-title":"Sci Transl Med"},{"key":"14885_CR29","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.lungcan.2019.11.018","volume":"139","author":"S Yang","year":"2020","unstructured":"Yang S, Mao S, Li X, Zhao C, Liu Q, Yu X, et al. Uncommon EGFR mutations associate with lower incidence of T790M mutation after EGFR-TKI treatment in patients with advanced NSCLC. Lung Cancer. 2020;139:133\u20139.","journal-title":"Lung Cancer"},{"issue":"12","key":"14885_CR30","first-page":"e12128","volume":"12","author":"I Pereira","year":"2020","unstructured":"Pereira I, Gaspar C, Pina M, Azevedo I, Rodrigues A, Real-World. T790M mutation frequency and impact of rebiopsy in patients with EGFR-Mutated advanced Non-Small cell lung cancer. Cureus. 2020;12(12):e12128.","journal-title":"Cureus"},{"issue":"11","key":"14885_CR31","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1038\/s41419-022-05408-1","volume":"13","author":"X Chen","year":"2022","unstructured":"Chen X, Zhang T, Su W, Dou Z, Zhao D, Jin X, et al. Mutant p53 in cancer: from molecular mechanism to therapeutic modulation. Cell Death Dis. 2022;13(11):974.","journal-title":"Cell Death Dis"},{"key":"14885_CR32","first-page":"583929","volume":"2011","author":"A Mogi","year":"2011","unstructured":"Mogi A, Kuwano H. TP53 mutations in nonsmall cell lung cancer. J Biomed Biotechnol. 2011;2011:583929.","journal-title":"J Biomed Biotechnol"},{"key":"14885_CR33","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2019.01367","volume":"10","author":"C Zhou","year":"2019","unstructured":"Zhou C, Li W, Shao J, Zhao J, Chen C. Analysis of the clinicopathologic characteristics of lung adenocarcinoma with CTNNB1 mutation. Front Genet. 2019;10: 1367.","journal-title":"Front Genet"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-14885-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-025-14885-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-14885-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T13:49:28Z","timestamp":1767707368000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12885-025-14885-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,27]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["14885"],"URL":"https:\/\/doi.org\/10.1186\/s12885-025-14885-4","relation":{},"ISSN":["1471-2407"],"issn-type":[{"type":"electronic","value":"1471-2407"}],"subject":[],"published":{"date-parts":[[2025,11,27]]},"assertion":[{"value":"27 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was carried out in compliance with the Declaration of Helsinki and was approved by the Medical Ethics Committee of Nanjing Geneseeq Medical Laboratory (NSJB-MEC-2024-03). Written informed consent was obtained from each patient before sample collection.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"J.P., J.C.Y., and C.H. are employees of Nanjing Geneseeq Technology Inc. All other authors declare that they have no conflicts of interest regarding the research presented in this manuscript.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"18"}}